AGARWALEYE Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹614 Cr
verified against source
Revenue YoY
26%
reported change
EBITDA
₹177 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Dr. Agarwal's Healthcare delivered a record-breaking Q1 FY27 with 614 crores in revenue from operations, growing 26% YoY and 8.8% sequentially — the strongest quarterly growth. EBITDA stood at 177 crores with 28.5% margin (up 30bps YoY), while PAT margin expanded by 127bps to 8.9%. The company launched a record 16 surgical facilities in one quarter, taking the total network to 285 facilities across 14 states. Surgical volumes grew 15.5% to ~91,000 surgeries, while premium procedures (robotic cataract, SMILE, retinal) grew 30-36% YoY, demonstrating successful premiumization. The North region is the fastest-growing at 50.5% YoY with strong Delhi NCR traction. Management guided for 60 new facilities in FY27 with 30+ signed LOIs in pipeline. Gross margins improved ~100bps from COGS optimization and lower finance costs. Risks include ~20 crores drag from new facility ramp-up losses and the mid-November merger completion timeline adding execution uncertainty.
Colored figures show movement against the previous available record.
Guidance to track
- Q1 delivered 18 facilities (16 surgical) setting rapid pace. Q2 targets 12 facilities with 30 in H2. Pipeline of 30+ signed LOIs provides visibility.
- Final closing items are in progress for the merger, expected to conclude around mid-November.
- Management expects to continue growth driven by existing facility ramp-up, new market entry, and accelerated adoption of innovative surgical procedures.
- While 16.3% SSSG delivered in Q1 for FY23-and-earlier cohort, management views 12-13% as sustainable long-term same-store growth for mature facilities.
Risks flagged
- New facilities (FY26 and FY27 vintages) are collectively running at ~20 crores loss level. These centers take ~3 years to mature, creating sustained drag on profitability as expansion accelerates.
- Delhi NCR and other northern facilities are far from mature state; surgeries per center in North are not close to South mature facility levels despite 50.5% growth rate, indicating long ramp-up runway required.
- Premium ARPU has grown from ~28,500 to ~42,000 over four years with ~10% value growth. Analyst questioned whether 10% ARPU growth is sustainable given base effect, and management could not provide specific guidance on trajectory.
- Management confirmed mid-November expected closure but described being 'in the process of closing some of the final items,' suggesting some execution uncertainty around the merger completion.
Key quotes
- This new fiscal year commenced with record-breaking results. This quarter, we launched 16 new surgical facilities, our highest ever in a single quarter, and delivered revenue from operations of 614 crores, growing 8.8% sequentially, also our strongest quarter growth.
- Our Greenfield engine has been the defining driver of our network growth over the last four years. Since FY23, we have added 166 new greenfield facilities, accelerating our expansion from 10 facility additions in FY23 to just 18 facilities in FY27 alone.
- In the last four months alone, we have added 100 new doctors to our network. In many of these centers especially in Maharashtra, Delhi and NCR many new doctors have joined the network. We will start to see improved improvements in their productivity as time goes by and as the centers start to mature.
Research modules